|Articles|April 10, 2009

Woty-Podcast-Kathy Giusti

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: FDA Approves Breyanzi

ByNicholas Jacobus

December 8th 2025

Image Credit: Adobe Stock Images/garrykillian

EU Opportunities: How EMA Support Programs Can Slash Drug Market Entry Costs by 90%

ByPhilip Raeth, MD

December 8th 2025

Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma

ByNicholas Jacobus

December 8th 2025

Future Phase III Trial Planning: Payer Point of View

ByIra Studin, PhD

December 8th 2025

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL

ByNicholas Jacobus

December 8th 2025

Woty-Podcast-Kathy Giusti

Newsletter

Related Content

Pharmaceutical Executive Daily: FDA Approves Breyanzi

EU Opportunities: How EMA Support Programs Can Slash Drug Market Entry Costs by 90%

Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma

Future Phase III Trial Planning: Payer Point of View

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL

Trending on PharmExec

Is FDA Streamlining Regulations in the Biosimilar Space?

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma